Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies
NCT07032727Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of olutasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2025; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07032727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032727.